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hypothesis for a central role of vascular oxidative stress in the develop-
ment of AsAA.
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The response of various systems to stressful stimuli is influenced by the
HPA axis. We investigated the contribution of the stress hormone corti-
cotropin (CRH) to cardiac function in basal and stressful conditions in Crh-
null (Crh –/–) and wild-type (Crh+/+) mice. The stressful/ inflammatory
reaction was induced by LPS. Heart Rate (HR), percentage of LV fractional
shortening (FS) and Ejection Fraction (EF) were calculated by echocardio-
graphy. At baseline, cardiac function was compromised in Crh –/– com-
pared to Crh+/+ mice, as shown by cardiac hypertrophy, significantly lower
FS and EF and lower heart rate. Crh –/– had increased levels of apoptosis,
increased perivascular fibrosis and vascular thickness. They exhibited
greatly reduced ERK1/2 and Akt phosphorylation and increased levels of
MMP13. LPS administration significantly reduced FS and EF at 6 and 20h
in Crh+/+ and more drastically in Crh –/– mice. LPS-treated mice had sig-
nificantly increased number of apoptotic cells. Their cardiac muscle showed
higher levels of infiltration and development of fibers surrounding the
hyperplastic vessels, in addition to increased fibrosis-like reactive collagen
production and fibronectin levels. LPS greatly increased levels of IL-6 and
TNF. MMP13, which contribute to the progression of cardiomyopathy
was further increased. Crh –/– had unexpected high levels of mortality (90-
100% 16-28h post-LPS treatment), compared to no mortality among Crh+/+.
To dissect the contribution of glucocorticoid insufficiency in Crh –/–, cor-
ticosterone was replaced for a week prior to LPS treatment, but that
improved the effect of LPS on Crh –/– only when accompanied with an
acute dexamethasone injection. To our knowledge, this is the first indica-
tion of endogenous CRH acting directly in cardiac function and develop-
ment under basal conditions and as a cardioprotective factor in response to
systemic inflammatory stress such as endotoxemia. 
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Atherosclerosis is an inflammatory disease in which the coordination of
angiogenesis and inflammation is achieved by the ability of both endothelial
cells and monocytes to respond to chemokines. We here addressed by both in
vitro and in vivo techniques, the influence of RANTES/CCL5 on angiogen-
esis, and the role of its cellular ligands CCR1, CCR5, syndecan-1 (SDC-1),
syndecan-4 (SDC-4), CD-44 in this effect. 
The angiogenic effects of RANTES/CCL5 or its mutants, [E66A] –
RANTES/CCL5 with impaired ability to oligomerize, and [44AANA47] –
RANTES/CCL5 mutated in the main RANTES/CCL5-GAGs binding site
were analyzed in vivo in a rat-disc model, and in vitro by measuring i/ their
effect on endothelial cell proliferation, migration, spreading and vessels for-
mation in 2D and 3D angiogenesis, ii/ the involvement of RANTES/CCL5
cellular ligands such as G Protein-Coupled Receptors and proteoglycans in
RANTES/CCL5-induced biological effects.
Our data demonstrate that RANTES/CCL5 is pro-angiogenic both in
vitro and in vivo experimental models. This activity depends on RANTES/
CCL5 binding to CCR1, CCR5, SDC-1, SDC-4 or CD-44. Moreover, oli-
gomerization and binding to glycosaminoglycans are essential steps in the
induction of RANTES/CCL5 angiogenic effects. Altogether our results
suggest that the induction of angiogenesis by the chemokine RANTES/
CCL5 lead to new therapeutic approaches for reendothelialization after
vascular injury.
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Objectives: It has been shown that blood levels of Lp-PLA2 predict future
cardiovascular events indepently from traditional cardiovascular risk factors.
Metabolic syndrome has been associated with an increased cardiovascular
risk. The aim of this study was to study the relationship between Lp-PLA2
and metabolic syndrome components.
Methods: Patients were recruited at our outpatient clinic. None should
have any history of cardiovascular diseaseand all underwent routine clinical
and biological assessments. Lp-PLA2 was measured in serum with a Plac Test
turbidimetric immunoassay.
Results: 148 patients were included with a mean age of 53 years. Lp-PLA2
levels ranged from 41 to 407 ng/mL with a mean of 189 ng/ mL (SD: 67 ng/mL).
119 patients (80%) presented with at least 3 NCEP ATPIII criteria of meta-
bolic syndrome and 61 (41) % had treatment for diabetes. 58 patients (39%)
were under statin treatment. Our results showed that neither the presence of
metabolic syndrome, nor the number of its components influenced Lp-PLA2
levels. We found no individual link between each component of the metabolic
syndrome and Lp-PLA2 levels except for diabetes mellitus. There was a neg-
ative correlation between diabetes and Lp-PLA2 that did not persist after
adjustment for lipid lowering treatments. In univariate analysis, we found a
strong linear correlation between Lp-PLA2, LDL-cholesterol (r=0.377
p<0.001). This association existed whereas patients were treated by statins or
not. Accordingly, a statin intake was associated with significantly lower Lp-
PLA2 levels (190 ng/mL vs. 148 ng/mL, p<0.001). There was no correlation
between other traditional risk factors (age, gender, smoking status, blood pres-
sure) and Lp-PLA2 levels.
Conclusion: In our eurocaucasian population of patients with metabolic
syndrome in primary prevention, we confirmed that Lp-PLA2 levels were
totally independent of the components of metabolic syndrome and of any tra-
ditional risk factors. In the opposite, they were strongly correlated with LDL-
C and statin intake. It highlights the fact that interpretation of Lp-PLA2 assay
may need to be adjusted for LDL-C level and lipid lowering therapy to be
completely accurate.
295
Influence of endothelial nitric oxide synthase gene polymorphisms
(894G>T, –786T>C, 4a4b) in Tunisian patients with myocardial
infarction
Riadh Jemaa [Orateur] (1), Amani Kallel (1), Yousra Sediri (1), Moncef
Feki (1), Mhammed Sami Mourali (2), Salem Abdessalem (2), Rachid
Mechmeche (2), Naziha Kaabachi (1)
(1) Hôpital la Rabta, Biochimie, Tunis, Tunisie – (2) Hôpital la Rabta,
Cardiologie, Tunis, Tunisie
Introduction: The 894G>T, –786T>C and 4a4b polymorphisms of the
NOS3 gene have been associated with coronary artery disease (CAD) in sev-
eral populations worldwide, but results are still controversial. In the present
study, we examined the association between the 894G>T, –786T>C and 4a4b
polymorphisms of the NOS3 gene and myocardial infarction (MI) in a sample
of the Tunisian population.
Methods: A total of 303 unrelated patients with MI and 225 controls were
included in this study. The 8940G>T and -786T>C single nucleotide polymor-
phisms were analyzed by PCR-RFLP, and 4a4b polymorphism by PCR.
Results: The genotype distribution and the relative allelic frequencies for
the 894G>T and –786T>C polymorphisms were not significantly different
between MI and control subjects (p = NS). Moreover, the odds ratio for MI
associated with the 894T (OR = 1.02, 95% CI 0.76-1.35), –786C (OR = 1.09,
